Lipid-lowering long-term effects of six different statins in hypercholesterolemic renal transplant patients under cyclosporine immunosuppression

Martínez‐Castelao, Alberto; Grinyó, Josep M.; Gil-Vernet, S.; Serón, Daniel; Castiñeiras, M J; Ramos, Rosa; Alsina, J

doi:10.1016/s0041-1345(01)02836-6

Cited by 20 publications

(15 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2). The effects on HDL cholesterol and triglycerides varied between agents, again as reported in the general population [29]. …”

Section: Efficacy Comparison Between Statins In the Renal Disease Popmentioning

confidence: 68%

“…Few studies have analyzed the effect of statin therapy on lipid parameters in renal transplant patients, but the available evidence does not indicate any lessening of lipid-lowering efficacy as compared with the non-transplant population [29, 30]. …”

Section: Regulation Of Dyslipidaemia In Renal Disease Using Statin Thmentioning

confidence: 99%

“…To date, very few studies have compared the efficacy of statins in the renal disease population. Martínez-Castelao et al [29]retrospectively evaluated the relative efficacy of six different statins in hypercholestolaemic renal transplant patients. One hundred and twenty-two patients received a single dose of a statin for 12 months, starting with a low dose and titrating upwards as necessary.…”

Section: Efficacy Comparison Between Statins In the Renal Disease Popmentioning

confidence: 99%

“…2 Percentage reduction in total cholesterol and LDL cholesterol in hypercholesterolaemic renal transplant patients after 1 year of treatment [29]. …”

Section: Efficacy Comparison Between Statins In the Renal Disease Popmentioning

confidence: 99%

“…Newer statins such as atorvastatin have been shown to achieve greater reductions in total cholesterol and LDL cholesterol than conventional statins, including simvastatin and pravastatin [29, 43]. To achieve the same degree of efficacy has previously required a combination therapy with a statin and another hypolipidaemic agent such as a fibrate, with implications for tolerance and compliance.…”

Section: Treatment Strategymentioning

confidence: 99%

See 4 more Smart Citations

Therapeutic Considerations for the Use of Statin Therapy in Chronic Renal Disease

Moore

2004

Nephron Clin Pract

View full text Add to dashboard Cite

This review presents an evidence-based analysis of the use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) in patients with chronic renal disease. It considers the characteristics and incidence of dyslipidaemia among specific patient types and describes the available data concerning the ability of statin therapy to regulate dyslipidaemia in the renal disease population as well as early results for an anti-inflammatory effect in this group. The clinical impact of statins in terms of reduced morbidity and mortality is also discussed. The relative merits of different statin agents are reviewed in terms of efficacy and safety, together with the role of aggressive intervention as compared with standard approaches to care. Finally, a proposed algorithm for the initiation and monitoring of statin therapy in chronic renal disease patients is presented.

show abstract

“…2). The effects on HDL cholesterol and triglycerides varied between agents, again as reported in the general population [29]. …”

Section: Efficacy Comparison Between Statins In the Renal Disease Popmentioning

confidence: 68%

Section: Regulation Of Dyslipidaemia In Renal Disease Using Statin Thmentioning

confidence: 99%

Section: Efficacy Comparison Between Statins In the Renal Disease Popmentioning

confidence: 99%

“…2 Percentage reduction in total cholesterol and LDL cholesterol in hypercholesterolaemic renal transplant patients after 1 year of treatment [29]. …”

Section: Efficacy Comparison Between Statins In the Renal Disease Popmentioning

confidence: 99%

Section: Treatment Strategymentioning

confidence: 99%

See 3 more Smart Citations